
Definium Therapeutics, Inc.
93
Recent developments for Definium Therapeutics include reporting third quarter 2026 financial results, detailed earnings call discussions, and multiple updates on Phase III clinical trial progress and successes for DT120 in anxiety and depression.
- Definium Therapeutics reported third quarter 2026 financial results, including a net loss of approximately $50.96 million and strong liquidity with over $1 billion in current assets as of September 30, 2026 [N1][S2].
- The company held its Q3 2026 earnings call, providing detailed updates on clinical trial progress and strategic initiatives [N2][N3].
- Definium highlighted Phase III clinical trial gains for DT120 in anxiety and depression, reporting that the candidate met key Phase III goals in generalized anxiety disorder studies [N4][N5].
- The company continues to advance its Phase 3 clinical programs for DT120 in generalized anxiety disorder and major depressive disorder, with topline readouts anticipated in 2026 [N4][N5].
Definium Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders using psychedelics and empathogens. Its lead candidate, DT120, is a proprietary lysergide D-tartrate formulation targeting generalized anxiety disorder and major depressive disorder, with Phase 3 trials underway following positive Phase 2b results and FDA breakthrough designation. The company also develops DT402, a proprietary R(-)-MDMA formulation for autism spectrum disorder, currently in Phase 2a trials. Definium's strategy includes advancing clinical programs, submitting regulatory applications, commercializing approved products, expanding indications, and exploring collaborations. The company maintains strong liquidity with over $1 billion in current assets as of Q3 2026 [S1][S2].
Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing pharmaceutically optimized psychedelics for brain health disorders, primarily focusing on its lead product candidates DT120 and DT402. DT120 is in Phase 3 trials for generalized anxiety disorder and major depressive disorder, having demonstrated positive Phase 2b results and received FDA breakthrough designation. DT402 is in early Phase 2a trials for autism spectrum disorder. As of September 30, 2026, the company reported strong liquidity with over $1 billion in current assets and a net loss of approximately $51 million for the quarter. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Recent news coverage highlights ongoing clinical progress and financial reporting [S1][S2][N1][N2][N3][N4][N5].
Definium's lead candidate DT120 has demonstrated statistically significant and clinically meaningful improvements in Phase 2b trials for generalized anxiety disorder, with rapid and durable effects. The FDA breakthrough designation and Innovation Passport in the UK facilitate regulatory pathways. The ongoing Phase 3 trials for GAD and MDD, along with early Phase 2a trials for DT402 in autism spectrum disorder, represent key clinical milestones. Strong liquidity supports continued development and potential commercialization efforts. Positive clinical data and regulatory progress could enhance the company's position in the emerging psychedelic therapeutics market [S1][N4][N5].
Definium faces risks typical of clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes, regulatory approval challenges, and the need for substantial capital to fund ongoing development. The company reported a net loss of approximately $51 million in Q3 2026, reflecting ongoing expenses without current product revenue. Market conditions and competition in the brain health disorder treatment space may impact future opportunities. Delays or negative results in pivotal trials could affect the company's strategic plans and valuation [S2].
Definium Therapeutics' moat is based on its proprietary pharmaceutically optimized psychedelic compounds, particularly DT120 and DT402, and its advanced clinical-stage pipeline targeting brain health disorders with limited recent innovation. The FDA breakthrough designation for DT120 and the Innovation Passport in the UK provide regulatory advantages. The company's focus on rigorous clinical development, adaptive trial designs, and intellectual property portfolio expansion supports potential competitive differentiation. However, the moat is contingent on successful clinical outcomes and regulatory approvals [S1].
• Clinical Trial Risk: The success of Definium's business depends on positive outcomes from ongoing Phase 3 trials for DT120 and Phase 2a trials for DT402. Negative or inconclusive results could delay or prevent regulatory approvals.
• Regulatory Risk: Obtaining FDA and other regulatory approvals is uncertain and may require additional data or trials, potentially impacting timelines and costs.
• Financial Risk: The company reported net losses and relies on its cash reserves and investments to fund operations. Insufficient capital or increased expenses could constrain development activities.
• Market and Competitive Risk: The brain health therapeutics market is competitive and evolving, with alternative treatments and new entrants potentially affecting Definium's market opportunities.
Business trends: Advancement of Phase 3 clinical trials for DT120 in anxiety and depression, initiation of Phase 2a trials for DT402 in autism spectrum disorder, and regulatory designations supporting development.
Execution milestones: Completion and topline readouts of pivotal Phase 3 trials for DT120, ongoing enrollment and data collection in MDD and GAD studies, and initial Phase 2a data for DT402.
Key risks: Clinical trial outcomes uncertainty, regulatory approval challenges, financial sustainability amid net losses, and competitive pressures in brain health therapeutics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel product candidates to treat brain health disorders, specifically using pharmaceutically optimized psychedelics and empathogens such as DT120 and DT402 [S1].
- DT120 ODT is a proprietary form of lysergide D-tartrate being developed for generalized anxiety disorder (GAD) and major depressive disorder (MDD) [S1].
- DT120 demonstrated statistically significant and clinically meaningful improvements in Phase 2b trials for GAD, with rapid onset and durable effects up to 12 weeks [S1].
- The FDA granted breakthrough therapy designation to DT120 for GAD in March 2024 [S1].
- Definium is conducting Phase 3 clinical trials for DT120 in GAD (Voyage and Panorama studies) and MDD (Emerge and Ascend studies), with adaptive trial designs and topline readouts anticipated in 2026 [S1].
- DT402 (R(-)-MDMA) is being developed for autism spectrum disorder (ASD), with Phase 2a trials initiated in late 2025 to assess early efficacy signals [S1].
- The company changed its name from Mind Medicine Inc. to Definium Therapeutics, Inc. in January 2026 and trades under ticker DFTX [S1].
- As of September 30, 2026, Definium had $241.15 million in cash and equivalents and $805.7 million in short-term investments, totaling over $1 billion in current assets against $67.73 million in current liabilities, resulting in a current ratio of 15.53 and a cash ratio of 15.46, indicating strong liquidity [S2].
- For the quarter ended September 30, 2026, Definium reported a net loss of $50.96 million and basic and diluted EPS of -$0.37 and -$0.46 respectively [S2].
- Recent news highlights include reporting third quarter 2026 financial results, Q3 earnings call transcripts, and multiple updates on Phase III clinical trial progress and successes for DT120 in anxiety and depression [N1][N2][N3][N4][N5].
Generated 2026-11-11
- N2
- S1 | 2026-02-26 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Definium Therapeutics Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/definium-therapeutics-reports-third-quarter-2026-financial-results
- N2 | 2026-11-10 | www.nasdaq.com | Definium (DFTX) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/definium-dftx-q3-2026-earnings-call-transcript
- N3 | 2026-11-10 | www.nasdaq.com | What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call | https://www.nasdaq.com/articles/what-definium-therapeutics-dftx-said-its-q3-earnings-call
- N4 | 2026-09-24 | www.nasdaq.com | Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression | https://www.nasdaq.com/articles/definium-therapeutics-highlights-phase-iii-dt120-gains-anxiety-and-depression
- N5 | 2026-09-19 | www.nasdaq.com | Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study | https://www.nasdaq.com/articles/definium-therapeutics-dt120-hits-phase-iii-goals-anxiety-study
- N6 | 2026-09-15 | www.nasdaq.com | Stocks Settle Lower as AI Slowdown Fears Weigh on Chipmakers | https://www.nasdaq.com/articles/stocks-settle-lower-ai-slowdown-fears-weigh-chipmakers
- N7 | 2026-09-14 | www.nasdaq.com | Stocks Fall on AI Slowdown Fears and Rising Crude Oil Prices | https://www.nasdaq.com/articles/stocks-fall-ai-slowdown-fears-and-rising-crude-oil-prices
- N8 | 2026-09-14 | www.nasdaq.com | Stocks Slump on AI Slowdown Fears and Rising Bond Yields and Crude Prices | https://www.nasdaq.com/articles/stocks-slump-ai-slowdown-fears-and-rising-bond-yields-and-crude-prices
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


